Mechanistic Basis of pH-Dependent 5-Flucytosine Resistance in Aspergillus fumigatus
- PMID: 29610197
- PMCID: PMC5971587
- DOI: 10.1128/AAC.02593-17
Mechanistic Basis of pH-Dependent 5-Flucytosine Resistance in Aspergillus fumigatus
Abstract
The antifungal drug 5-flucytosine (5FC), a derivative of the nucleobase cytosine, is licensed for the treatment of fungal diseases; however, it is rarely used as a monotherapeutic to treat Aspergillus infection. Despite being potent against other fungal pathogens, 5FC has limited activity against Aspergillus fumigatus when standard in vitro assays are used to determine susceptibility. However, in modified in vitro assays where the pH is set to pH 5, the activity of 5FC increases significantly. Here we provide evidence that fcyB, a gene that encodes a purine-cytosine permease orthologous to known 5FC importers, is downregulated at pH 7 and is the primary factor responsible for the low efficacy of 5FC at pH 7. We also uncover two transcriptional regulators that are responsible for the repression of fcyB and, consequently, mediators of 5FC resistance, the CCAAT binding complex (CBC) and the pH regulatory protein PacC. We propose that the activity of 5FC might be enhanced by the perturbation of factors that repress fcyB expression, such as PacC or other components of the pH-sensing machinery.
Keywords: 5-flucytosine; Aspergillus fumigatus; CBC; antifungal agents; antifungal drug resistance; pH regulation; pacC; transcription factors.
Copyright © 2018 American Society for Microbiology.
Figures





References
-
- Grunberg E, Titsworth E, Bennett M. 1963. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother 161:566–568. - PubMed
-
- Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50:291–322. doi:10.1086/649858. - DOI - PMC - PubMed
-
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:409–417. doi:10.1093/cid/civ1194. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources